CoChat

Combined PD-1, BRAF and MEK inhibition in BRAFV600E colorectal cancer: a phase 2 trial

Open access
Tian, Jun, Chen, Jonathan H., Chao, Sherry X., Pelka, Karin, Giannakis, Marios, Hess, Julian, Burke, Kelly, Jorgji, Vjola, Sindurakar, Princy, Braverman, Jonathan, Mehta, Arnav, Oka, Tomonori, Huang, Mei, Lieb, David, Spurrell, Maxwell, Allen, Jill N., Abrams, Thomas A., Clark, Jeffrey W., Enzinger, Andrea C., Enzinger, Peter C., Klempner, Samuel J., McCleary, Nadine J., Meyerhardt, Jeffrey A., Ryan, David P., Yurgelun, Matthew B., Kanter, Katie, Van Seventer, Emily E., Baiev, Islam, Chi, Gary, Jarnagin, Joy, Bradford, William B., Wong, Edmond, Michel, Alexa G., Fetter, Isobel J., Siravegna, Giulia, Gemma, Angelo J., Sharpe, Arlene, Demehri, Shadmehr, Leary, Rebecca, Campbell, Catarina D., Yilmaz, Omer, Getz, Gad A., Parikh, Aparna R., Hacohen, Nir, Corcoran, Ryan B. · 2023 · Nature Medicine
Cited by 198

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Abstract

While BRAF inhibitor combinations with EGFR and/or MEK inhibitors have improved clinical efficacy in BRAF V600E colorectal cancer (CRC), response rates remain low and lack durability. Preclinical data suggest that BRAF/MAPK pathway inhibition may augment the tumor immune response. We performed a proof-of-concept single-arm phase 2 clinical trial of combined PD-1, BRAF and MEK inhibition with sparatlizumab (PDR001), dabrafenib and trametinib in 37 patients with BRAF V600E CRC. The primary end point was overall response rate, and the secondary end points were progression-free survival, disease control rate, duration of response and overall survival. The study met its primary end point with a confirmed response rate (24.3% in all patients; 25% in microsatellite stable patients) and durability that were favorable relative to historical controls of BRAF-targeted combinations alone. Single-cell RNA sequencing of 23 paired pretreatment and day 15 on-treatment tumor biopsies revealed greater induction of tumor cell-intrinsic immune programs and more complete MAPK inhibition in patients with better clinical outcome. Immune program induction in matched patient-derived organoids correlated with the degree of MAPK inhibition. These data suggest a potential tumor cell-intrinsic mechanism of cooperativity between MAPK inhibition and immune response, warranting further clinical evaluation of optimized targeted and immune combinations in CRC. ClinicalTrials.gov registration: NCT03668431.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41591-022-02181-8

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 22 references

Cited by

See all 198

Metadata

Authors
Tian, J., Chen, J. H., Chao, S. X., Pelka, K., Giannakis, M., Hess, J., Burke, K., Jorgji, V., Sindurakar, P., Braverman, J., Mehta, A., Oka, T., Huang, M., Lieb, D., Spurrell, M., Allen, J. N., Abrams, T. A., Clark, J. W., Enzinger, A. C., Enzinger, P. C., Klempner, S. J., McCleary, N. J., Meyerhardt, J. A., Ryan, D. P., Yurgelun, M. B., Kanter, K., Van Seventer, E. E., Baiev, I., Chi, G., Jarnagin, J., Bradford, W. B., Wong, E., Michel, A. G., Fetter, I. J., Siravegna, G., Gemma, A. J., Sharpe, A., Demehri, S., Leary, R., Campbell, C. D., Yilmaz, O., Getz, G. A., Parikh, A. R., Hacohen, N., & Corcoran, R. B.
Venue
Nature Medicine
Published
2023-01-26
Volume
29
Issue
2
Pages
458-466
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W4318071509
Cited by
198
References
22
FWCI
20.60
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Combined PD-1, BRAF and MEK inhibition in BRAFV600E colorectal cancer: a phase 2 trial. https://app.cochat.ai/papers/10.1038/s41591-022-02181-8
The paper
Tian, J., Chen, J. H., Chao, S. X., Pelka, K., Giannakis, M., Hess, J., Burke, K., Jorgji, V., Sindurakar, P., Braverman, J., Mehta, A., Oka, T., Huang, M., Lieb, D., Spurrell, M., Allen, J. N., Abrams, T. A., Clark, J. W., Enzinger, A. C., . . . Corcoran, R. B. (2023). Combined PD-1, BRAF and MEK inhibition in BRAFV600E colorectal cancer: a phase 2 trial. Nature Medicine. https://doi.org/10.1038/s41591-022-02181-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.